Application of Organoids in Gynecological Malignant Tumors

doi:10.12280/gjfckx.20210751

Abstract

Abstract:

Organoids, as micro-organs with three-dimensional structures, can highly mimic the morphological structure and physiological functions of the source tissues, and cultivate tissue structures with stable phenotypes. Organoids are good models for basic and clinical researches. Organoids have great potential applications and can be used as in vitro models for various types of biomedical research. Organoids are of great significance in the research of growth and development, organ transplantation, signal transduction pathways, drug development, high-throughput drug screening, and individualized treatment of tumors. Studies have shown that organoids are novel and reliable clinical models for gynecological malignant tumor researches, which can play important roles in the precise and individualized treatment of patients. This article briefly reviews the molecular mechanism and drug screening of organoids in ovarian cancer, endometrial cancer, cervical cancer and other gynecological malignancies.

Key words: Organoids, Genital neoplasms,female, Carcinoma, Drug screening assays,antitumor, Tumor models

WU Jia-xing, WANG Xi-peng. Application of Organoids in Gynecological Malignant Tumors[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 186-190.

Figures/Tables 2

References 38

[1]	Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies[J]. Science, 2014, 345(6194):1247125. doi: 10.1126/science.1247125. doi: 10.1126/science.1247125
[2]	Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease[J]. Nat Cell Biol, 2016, 18(3):246-254. doi: 10.1038/ncb3312. doi: 10.1038/ncb3312 pmid: 26911908
[3]	Lee YY, Choi MC, Park JY, et al. Major clinical research advances in gynecologic cancer in 2020[J]. J Gynecol Oncol, 2021, 32(4):e53. doi: 10.3802/jgo.2021.32.e53. doi: 10.3802/jgo.2021.32.e53
[4]	Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells[J]. Cell, 1975, 6(3):331-343. doi: 10.1016/s0092-8674(75)80001-8. doi: 10.1016/s0092-8674(75)80001-8 pmid: 1052771
[5]	Lindberg K, Brown ME, Chaves HV, et al. In vitro propagation of human ocular surface epithelial cells for transplantation[J]. Invest Ophthalmol Vis Sci, 1993, 34(9):2672-2679.
[6]	Pellegrini G, Traverso CE, Franzi AT, et al. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium[J]. Lancet, 1997, 349(9057):990-993. doi: 10.1016/S0140-6736(96)11188-0. doi: 10.1016/S0140-6736(96)11188-0 pmid: 9100626
[7]	Barker N, Huch M, Kujala P, et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro[J]. Cell Stem Cell, 2010, 6(1):25-36. doi: 10.1016/j.stem.2009.11.013. doi: 10.1016/j.stem.2009.11.013 pmid: 20085740
[8]	Sato T, Vries RG, Snippert HJ, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009, 459(7244):262-265. doi: 10.1038/nature07935. doi: 10.1038/nature07935
[9]	Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett′s epithelium[J]. Gastroenterology, 2011, 141(5):1762-1772. doi: 10.1053/j.gastro.2011.07.050. doi: 10.1053/j.gastro.2011.07.050
[10]	Mariani J, Simonini MV, Palejev D, et al. Modeling human cortical development in vitro using induced pluripotent stem cells[J]. Proc Natl Acad Sci U S A, 2012, 109(31):12770-12775. doi: 10.1073/pnas.1202944109. doi: 10.1073/pnas.1202944109
[11]	Mondrinos MJ, Jones PL, Finck CM, et al. Engineering de novo assembly of fetal pulmonary organoids[J]. Tissue Eng Part A, 2014, 20(21/22):2892-2907. doi: 10.1089/ten.TEA.2014.0085. doi: 10.1089/ten.TEA.2014.0085
[12]	McCracken KW, Catá EM, Crawford CM, et al. Modelling human development and disease in pluripotent stem-cell-derived gastric organoids[J]. Nature, 2014, 516(7531):400-404. doi: 10.1038/nature13863. doi: 10.1038/nature13863
[13]	Karthaus WR, Iaquinta PJ, Drost J, et al. Identification of multipotent luminal progenitor cells in human prostate organoid cultures[J]. Cell, 2014, 159(1):163-175. doi: 10.1016/j.cell.2014.08.017. doi: S0092-8674(14)01048-4 pmid: 25201529
[14]	Greggio C, De Franceschi F, Figueiredo-Larsen M, et al. Artificial three-dimensional niches deconstruct pancreas development in vitro[J]. Development, 2013, 140(21):4452-4462. doi: 10.1242/dev.096628. doi: 10.1242/dev.096628 pmid: 24130330
[15]	Xia Y, Nivet E, Sancho-Martinez I, et al. Directed differentiation of human pluripotent cells to ureteric bud kidney progenitor-like cells[J]. Nat Cell Biol, 2013, 15(12):1507-1515. doi: 10.1038/ncb2872. doi: 10.1038/ncb2872
[16]	Huch M, Dorrell C, Boj SF, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration[J]. Nature, 2013, 494(7436):247-250. doi: 10.1038/nature11826. doi: 10.1038/nature11826
[17]	Sachs N, de Ligt J, Kopper O, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity[J]. Cell, 2018, 172(1/2):373-386.e10. doi: 10.1016/j.cell.2017.11.010. doi: 10.1016/j.cell.2017.11.010
[18]	Lee SH, Hu W, Matulay JT, et al. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer[J]. Cell, 2018, 173(2):515-528.e17. doi: 10.1016/j.cell.2018.03.017. doi: 10.1016/j.cell.2018.03.017
[19]	Turco MY, Gardner L, Kay RG, et al. Trophoblast organoids as a model for maternal-fetal interactions during human placentation[J]. Nature, 2018, 564(7735):263-267. doi: 10.1038/s41586-018-0753-3. doi: 10.1038/s41586-018-0753-3
[20]	Kwong J, Chan FL, Wong KK, et al. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells[J]. Neoplasia, 2009, 11(6):529-541. doi: 10.1593/neo.09112. doi: 10.1593/neo.09112
[21]	Villa PL, Jackson R, Eade S, et al. Isolation of Biopsy-Derived, Human Cervical Keratinocytes Propagated as Monolayer and Organoid Cultures[J]. Sci Rep, 2018, 8(1):17869. doi: 10.1038/s41598-018-36150-4. doi: 10.1038/s41598-018-36150-4
[22]	Turco MY, Gardner L, Hughes J, et al. Long-term, hormone-responsive organoid cultures of human endometrium in a chemically defined medium[J]. Nat Cell Biol, 2017, 19(5):568-577. doi: 10.1038/ncb3516. doi: 10.1038/ncb3516
[23]	Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer[J]. Cell, 2014, 159(1):176-187. doi: 10.1016/j.cell.2014.08.016. doi: 10.1016/j.cell.2014.08.016
[24]	Heremans R, Jan Z, Timmerman D, et al. Organoids of the Female Reproductive Tract: Innovative Tools to Study Desired to Unwelcome Processes[J]. Front Cell Dev Biol, 2021, 9:661472. doi: 10.3389/fcell.2021.661472. doi: 10.3389/fcell.2021.661472
[25]	Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41:3-14. doi: 10.1016/j.bpobgyn.2016.08.006. doi: 10.1016/j.bpobgyn.2016.08.006
[26]	Hill SJ, Decker B, Roberts EA, et al. Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids[J]. Cancer Discov, 2018, 8(11):1404-1421. doi: 10.1158/2159-8290.CD-18-0474. doi: 10.1158/2159-8290.CD-18-0474
[27]	Soragni A, Janzen DM, Johnson LM, et al. A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas[J]. Cancer Cell, 2016, 29(1):90-103. doi: 10.1016/j.ccell.2015.12.002. doi: 10.1016/j.ccell.2015.12.002 pmid: 26748848
[28]	Yuki K, Cheng N, Nakano M, et al. Organoid Models of Tumor Immunology[J]. Trends Immunol, 2020, 41(8):652-664. doi: 10.1016/j.it.2020.06.010. doi: 10.1016/j.it.2020.06.010
[29]	Boretto M, Cox B, Noben M, et al. Development of organoids from mouse and human endometrium showing endometrial epithelium physiology and long-term expandability[J]. Development, 2017, 144(10):1775-1786. doi: 10.1242/dev.148478. doi: 10.1242/dev.148478 pmid: 28442471
[30]	Zieba A, Sjöstedt E, Olovsson M, et al. The Human Endometrium-Specific Proteome Defined by Transcriptomics and Antibody-Based Profiling[J]. OMICS, 2015, 19(11):659-668. doi: 10.1089/omi.2015.0115. doi: 10.1089/omi.2015.0115
[31]	Hennes A, Held K, Boretto M, et al. Functional expression of the mechanosensitive PIEZO1 channel in primary endometrial epithelial cells and endometrial organoids[J]. Sci Rep, 2019, 9(1):1779. doi: 10.1038/s41598-018-38376-8. doi: 10.1038/s41598-018-38376-8
[32]	Girda E, Huang EC, Leiserowitz GS, et al. The Use of Endometrial Cancer Patient-Derived Organoid Culture for Drug Sensitivity Testing Is Feasible[J]. Int J Gynecol Cancer, 2017, 27(8):1701-1707. doi: 10.1097/IGC.0000000000001061. doi: 10.1097/IGC.0000000000001061
[33]	Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers[J]. Science, 2018, 359(6378):920-926. doi: 10.1126/science.aao2774. doi: 10.1126/science.aao2774 pmid: 29472484
[34]	Lõhmussaar K, Oka R, Espejo Valle-Inclan J, et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer[J]. Cell Stem Cell, 2021, 28(8):1380-1396.e6. doi: 10.1016/j.stem.2021.03.012. doi: 10.1016/j.stem.2021.03.012 pmid: 33852917
[35]	Matano M, Date S, Shimokawa M, et al. Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids[J]. Nat Med, 2015, 21(3):256-262. doi: 10.1038/nm.3802. doi: 10.1038/nm.3802 pmid: 25706875
[36]	Zhang J, Rashmi R, Inkman M, et al. Integrating imaging and RNA-seq improves outcome prediction in cervical cancer[J]. J Clin Invest, 2021, 131(5):e139232. doi: 10.1172/JCI139232. doi: 10.1172/JCI139232
[37]	Maru Y, Tanaka N, Ebisawa K, et al. Establishment and characterization of patient-derived organoids from a young patient with cervical clear cell carcinoma[J]. Cancer Sci, 2019, 110(9):2992-3005. doi: 10.1111/cas.14119. doi: 10.1111/cas.14119
[38]	Fong E, Toh TB, Lin Q, et al. Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer[J]. Biomaterials, 2018, 159:229-240. doi: 10.1016/j.biomaterials.2017.12.026. doi: 10.1016/j.biomaterials.2017.12.026

类型	样本来源	首次报道时间（年）	主要技术方法
结肠^[8-9]	正常组织/ESC/iPSC/肿瘤	2009	基质胶
脑^[10]	ESC/iPSC	2012	SFEBq
肺^[11]	正常组织	2014	基质胶
胃^[12]	正常组织/肿瘤	2014	基质胶
前列腺^[13]	正常组织/肿瘤	2014	基质胶
胰腺^[14]	正常组织/肿瘤	2013	基质胶
肾^[15]	iPSC	2013	基质胶
肝^[16]	正常组织/iPSC/肿瘤	2013	基质胶
乳腺^[17]	肿瘤	2018	气液传递系统
膀胱^[18]	肿瘤	2018	基质胶
胎盘^[19]	正常组织/ESC/iPSC/肿瘤	2018	基质胶
卵巢^[20]	正常组织/ESC/iPSC/肿瘤	2009	基质胶
宫颈^[21]	正常组织/肿瘤	2018	基质胶
子宫内膜^[22]	正常组织/iPSC/肿瘤	2017	基质胶

类型	样本来源	首次报道时间（年）	主要技术方法
结肠^[8-9]	正常组织/ESC/iPSC/肿瘤	2009	基质胶
脑^[10]	ESC/iPSC	2012	SFEBq
肺^[11]	正常组织	2014	基质胶
胃^[12]	正常组织/肿瘤	2014	基质胶
前列腺^[13]	正常组织/肿瘤	2014	基质胶
胰腺^[14]	正常组织/肿瘤	2013	基质胶
肾^[15]	iPSC	2013	基质胶
肝^[16]	正常组织/iPSC/肿瘤	2013	基质胶
乳腺^[17]	肿瘤	2018	气液传递系统
膀胱^[18]	肿瘤	2018	基质胶
胎盘^[19]	正常组织/ESC/iPSC/肿瘤	2018	基质胶
卵巢^[20]	正常组织/ESC/iPSC/肿瘤	2009	基质胶
宫颈^[21]	正常组织/肿瘤	2018	基质胶
子宫内膜^[22]	正常组织/iPSC/肿瘤	2017	基质胶

培养技术	优势	缺陷
PDC	培养条件简单体外扩增快	扩增过程丧失异质性无法表达部分重要特征
PDX	肿瘤异质性完好保存体内微环境相互作用	模型构建难度大样本质量要求高试验周期长经济消耗大种属差异难以控制
PDO	可多次扩增传代保真度高培养周期短	样本取材易受干扰培养条件复杂缺乏肿瘤微环境和系统性

培养技术	优势	缺陷
PDC	培养条件简单体外扩增快	扩增过程丧失异质性无法表达部分重要特征
PDX	肿瘤异质性完好保存体内微环境相互作用	模型构建难度大样本质量要求高试验周期长经济消耗大种属差异难以控制
PDO	可多次扩增传代保真度高培养周期短	样本取材易受干扰培养条件复杂缺乏肿瘤微环境和系统性